The study follows people over time while they receive OM336 and regular checkups. A dose is given, and then health is monitored for side effects and other changes related to the immune system. If a kidney transplant happens during the study, follow-up continues after the transplant to watch for safety and other changes. The study lasts for about 2 years after treatment starts for each person, with repeated visits during that period.

The medications involved include canagliflozin, which is taken as a tablet, and a special version called 18F-canagliflozin. This second substance is a tracer used for PET imaging, a type of scan that allows doctors to see how substances move through the body. Participants will receive the medication through an intravenous administration, which means it is delivered directly into a vein through a needle. The study will also observe how these substances behave in patients with or without residual diuresis, which refers to the body’s remaining ability to produce urine.

The medication being tested, Veltassa, comes as a powder that is mixed with liquid and taken by mouth. Patients will receive either Veltassa or placebo for three months while continuing their regular dialysis treatment. During this time, doctors will monitor the amount of potassium in patients’ blood and assess whether they can safely include more potassium-containing foods in their diet.

The study will track several health factors, including changes in blood potassium levels, quality of life, and whether patients need additional treatments to manage their potassium levels. The research will also monitor if patients can better tolerate certain heart and blood pressure medications that are typically challenging to use in dialysis patients due to their effects on potassium levels.

Immunosuppression medications are drugs that reduce the activity of the immune system to prevent rejection of the transplanted kidney. However, these medications can have significant side effects, particularly in older adults. The purpose of this study is to determine if a reduced immunosuppression regimen can be as effective as the standard approach in terms of patient survival and transplant function.

Participants in this study will be randomly assigned to either the standard or reduced immunosuppression treatment group and followed for 12 months after their kidney transplant. During this time, researchers will monitor various outcomes including patient survival with functioning graft, complications, infections such as CMV (cytomegalovirus) and BK virus, and kidney function. The study will also assess quality of life measures and frailty before transplant and at the end of the 12-month period.

The purpose of this study is to evaluate the safety of PolyCore in patients who are starting peritoneal dialysis. The study will monitor participants for any side effects and changes in their health. Participants will receive the PolyCore solution through a process called intraperitoneal use, which means it is administered into the abdominal cavity. The study will involve regular check-ups where doctors will examine the participants, check their vital signs, and perform blood tests to ensure their safety.

Throughout the study, participants will have their kidney function and overall health closely monitored. This includes regular assessments of their blood chemistry, body weight, and the effectiveness of the dialysis treatment. The study aims to gather information on how well PolyCore works and how safe it is for people with End-Stage Kidney Disease who are undergoing peritoneal dialysis. The trial is expected to continue until 2027, providing valuable insights into the treatment of this serious condition.

Participants in the study will receive either mannitol or a placebo, which is a substance with no active treatment, through an intravenous infusion. The study will monitor how quickly the transplanted kidney begins to function and will also look at other factors such as the occurrence of acute kidney graft rejection within three months and the kidney’s performance at different time points, including seven days, one month, and three months after the transplant.

The trial aims to provide valuable information on whether mannitol can be a beneficial treatment option for improving outcomes in kidney transplant patients. The study will be conducted over a period of time, with participants being closely monitored to assess the effectiveness and safety of the treatment. This research could potentially lead to better management strategies for patients undergoing kidney transplantation, ultimately improving their quality of life.

Participants in the study will receive either the treatment with bRESCAP or a placebo, which is a substance with no active medication. The treatment is given as an IV infusion, which means it is administered directly into a vein. The study aims to see if the treatment can decrease the need for dialysis and improve kidney function after transplantation. The trial will also monitor other factors such as the length of hospital stay, kidney function over time, and any potential rejection of the transplanted kidney.

The study will follow participants for up to a year to gather comprehensive data on the effectiveness of the treatment. This includes measuring kidney function through tests like creatinine clearance and estimated glomerular filtration rate (eGFR), as well as checking for any signs of kidney rejection or other complications. The ultimate goal is to improve outcomes for patients receiving kidney transplants from donors who have experienced circulatory death.

The purpose of this study is to demonstrate the safety of Glucothera Plus in children who have End-stage Kidney Disease. During the study, participants will receive the treatment and be monitored for any side effects. The study will also involve regular checks of blood pressure, weight, and other health indicators to ensure the treatment is safe. The study will last for a period of up to four months, during which the participants will undergo various assessments to monitor their health and the effectiveness of the treatment.

Participants in the study will be children who are already receiving peritoneal dialysis. The study will involve regular visits to the clinic for monitoring and assessments. These assessments will include tests to measure kidney function, blood chemistry, and overall health. The goal is to ensure that Glucothera Plus is a safe option for children with End-stage Kidney Disease who require peritoneal dialysis.

The medications being studied include rituximab, azathioprine, prednisone, and mycophenolate mofetil. Rituximab is given as an injectable solution, while azathioprine, prednisone, and mycophenolate mofetil are taken orally in tablet form. The purpose of the study is to determine if stopping immunosuppressive therapy is better for patients with end-stage renal disease and ANCA vasculitis compared to continuing the standard maintenance therapy. The study will follow participants for 24 months to observe any severe events such as major relapses, severe infections, or death.

Participants in the study will be randomly assigned to either continue their current immunosuppressive therapy or to stop it. The study will monitor the health of the participants over the course of two years to see which approach leads to better outcomes. This research aims to provide valuable information on the best treatment approach for patients with these serious conditions.

Participants in the study will receive either the XyloCore solution or a standard glucose solution. The study will last for several months, during which participants will undergo regular assessments to monitor their health and the effectiveness of the treatment. These assessments will include tests to measure how well the dialysis is working, as well as checks on blood sugar and cholesterol levels, and evaluations of kidney function. Participants will also be asked about their energy levels and any side effects they may experience.

The purpose of this study is to determine if XyloCore is as effective as the standard treatments currently used for peritoneal dialysis. The study will help researchers understand if XyloCore can provide a safe and effective alternative for patients with End-Stage Kidney Disease. The trial is expected to continue until the end of 2025, with recruitment of participants having started in early 2023.

The purpose of the study is to find out if the 3HP or 4R treatment plans are better than the 3HR plan for helping patients complete their treatment for latent tuberculosis infection. Participants in the study will be randomly assigned to one of these three treatment plans. The study will monitor how well participants stick to their assigned treatment over a period of time. The treatments involve taking medication by mouth, and the study will track how many doses are completed within a set timeframe.

Throughout the study, researchers will also look at other factors, such as whether participants stop their treatment due to side effects and the overall number of participants who pass away during the study. The study aims to provide valuable information on the best way to treat latent tuberculosis infection in patients with end-stage kidney disease, helping to improve care for these individuals in the future.

Participants in the study will be given Apixaban, which is a type of medication known as an anticoagulant. Anticoagulants help prevent blood clots, which can lead to strokes. The study will compare the effects of taking Apixaban with not taking any anticoagulant medication. Some participants may receive a placebo, which looks like the medication but does not contain any active ingredients. The study will last for a period of up to 72 weeks, during which participants will take the medication orally, meaning they will swallow it in the form of a tablet.

The main goal is to determine if Apixaban can reduce the risk of having an ischemic stroke, which is a type of stroke caused by a blood clot blocking a blood vessel in the brain, or systemic embolism, which is when a blood clot travels to other parts of the body. The study will also monitor for any serious side effects, such as bleeding in the brain or other major bleeding events. Participants will be closely monitored throughout the study to ensure their safety and to gather information on the effectiveness of the treatment.